Wiley Interdisciplinary Reviews-Nanomedicine and NanobiotechnologyWiley跨学科评论：纳米医学与纳米生物技术
Wiley Interdisciplinary Reviews-Nanomedicine and Nanobiotechnology(英文缩写 WIRES NANOMED NANOBI),ISSN 1939-5116,eISSN 1939-0041,中文译名:Wiley跨学科评论：纳米医学与纳米生物技术 是一本学术期刊。本页汇总该期刊的最新影响因子、分区信息以及最新收录于 PubMed 的文献,帮助您快速了解期刊全貌。
发文量统计区间：2025-11-01 至 2026-10-31，按本站收录文献的发表日期统计。
期刊介绍
历年影响因子趋势
| JCR 数据年份 | 影响因子 | JCR 分区 |
|---|---|---|
| 2021 | 9.423 | Q1 |
| 2022 | 8.600 | Q1 |
| 2023 | 6.900 | Q1 |
| 2024 | 8.200 | Q1 |
| 2025 | 8.600 | Q1 |
Wiley Interdisciplinary Reviews-Nanomedicine and Nanobiotechnology 最新收录文献
-
1. Covalent Organic Frameworks as Next-Generation Photosensitizers: Mechanistic Underpinnings and Emerging Advances in Antimicrobial Photodynamic Therapy.
PMID:Antimicrobial photodynamic therapy (aPDT) offers a non-antibiotic strategy for combating drug-resistant and biofilm-associated infections, but conventional photosensitizers are limited by aggregation, poor targeting, hypoxia, and insufficient biofilm penetration. Covalent organic frameworks (COFs) provide structurally programmable platforms that can organize photoactive units, modulate excited-state evolution, regulate reactive oxygen species (ROS) generation, and integrate bacterial targeting or microenvironment-responsive functions. This review examines COF-based aPDT from a structure-photophysics-ROS-biological response perspective. We discuss the structural identity of COF-based platforms, core photodynamic mechanisms, photoactive building blocks, and enhancement strategies including metal coupling, targeting engineering, responsive release, photothermal assistance, and multimodal therapy. Current challenges, including mechanistic over-attribution, biofilm-relevant validation, oxygen dependence, stability, biosafety, and standardization, are critically analyzed. Finally, we highlight mechanism-guided design and translational evaluation as key requirements for advancing COF-based aPDT toward clinically relevant antimicrobial applications.
-
2. From Dilemma to Breakthrough: Prospects for Clinical Application of Exosome-Hydrogel Systems in Diabetic Wound Repair.
2. 从困境到突破：外泌体-水凝胶系统在糖尿病创面修复中的临床应用前景PMID:Diabetic wounds are refractory due to persistent inflammation and impaired angiogenesis, with traditional treatments having limited therapeutic effects. As promising cell-free therapeutic agents, exosomes can regulate wound inflammation and accelerate angiogenesis, while their clinical application is restricted by rapid in vivo clearance and short wound retention time. Functional hydrogels with excellent biocompatibility and sustained-release performance serve as ideal exosome carriers to construct intelligent composite dressings that break multiple healing barriers. This review summarizes the pathological mechanisms of diabetic wounds, the repair mechanisms of exosomes, and the fabrication strategies of exosome-loaded hydrogels. It also analyzes current challenges and prospects for the artificial intelligence-empowered research and clinical translation, providing theoretical references for the development of novel diabetic wound repair materials.
-
3. Brain-Targeting siRNA Delivery to Tackle Alzheimer's Disease.
3. 脑靶向siRNA递送治疗阿尔茨海默病PMID:Alzheimer's disease (AD) is a progressive neurodegenerative disorder that places an increasing burden on patients, caregivers, and healthcare systems worldwide. Current disease-modifying therapies (DMTs) are limited by high costs, complex administration, and reliance on advanced biomarker infrastructure, highlighting the shortcomings of existing treatment paradigms. These limitations have sparked growing interest in gene- and nucleic acid-based interventions as upstream strategies to modify AD pathogenesis. Among these, small interfering RNA (siRNA) is especially compelling because it can be rationally programmed, directed at multiple molecular pathways, and paired with rapidly evolving delivery technologies. However, the clinical translation of siRNA therapies for AD is still constrained by challenges in brain-targeted delivery, safety, and sustained efficacy. In this review, we summarize current concepts in AD pathology, highlight recent clinical and translational advances, and critically assess emerging brain-targeted siRNA delivery platforms and their key bottlenecks. Within a precision-medicine framework, brain-targeted siRNA offers the possibility of aligning patient selection, molecular targets, and delivery strategies with biomarker-defined AD endotypes. We discuss both the therapeutic promise and the realistic limitations of siRNA-based approaches for AD, outline priorities for future development, and identify key gaps that must be addressed to enable meaningful clinical implementation.
-
4. Breaking Physiological Barriers in Women's Health: Mucoadhesive and Stimuli-Responsive Nanomaterials.
PMID:Biomaterials are natural or synthetic molecules that exhibit biocompatibility, biodegradability, or bioresorbability. These materials are used for numerous health applications, including as drug delivery platforms. In drug delivery, biomaterials serve as drug carriers to enhance drug bioavailability and, consequently, treatment outcomes. Additionally, these biomaterial carriers may be functionalized to enhance targeting to a desired tissue. Specifically, in women's health, biomaterials may be designed to use the differences in pH, surface receptors, and cervicovaginal mucus in tissues such as the vagina, cervix, uterus, and ovaries to enhance local drug uptake. Recent advances in mucodiffusive drug delivery and stimuli-responsive drug delivery are furthering the fields of drug delivery and women's health.
-
5. Conditioned Media-Derived Tumor Extracellular Vesicles: Bridging Molecular Insights and Therapeutic Applications in Oncology.
5. 条件培养基来源的肿瘤细胞外囊泡：连接分子见解与肿瘤学治疗应用PMID:Tumor-derived extracellular vesicles (EVs) are major mediators of oncogenic intercellular communication. However, many studies using conditioned media (CM) recover operationally defined EV- or small EV-enriched fractions rather than biogenesis-proven exosomes. This review synthesizes evidence from CM-derived tumor EV studies and aligns their biological interpretation with current EV nomenclature, characterization, and reporting principles. We first discuss exosome biogenesis as a defined endosomal pathway and then examine how CM collection, serum handling, culture format, oxygen tension, conditioning interval, isolation strategy, storage, and co-isolated material shape EV yield, cargo composition, and apparent biological activity. Mechanistically, CM-based studies have clarified how tumor-derived EV-enriched preparations can support pre-metastatic niche formation, immune evasion through PD-L1 and regulatory RNA cargo, stromal and endothelial remodeling, angiogenesis, and therapy resistance. We also evaluate EV-associated miRNA and protein biomarkers as candidate liquid-biopsy analytes, emphasizing that their diagnostic value remains assay-, cohort-, and workflow-dependent. Therapeutically, the review distinguishes mechanisms inferred from CM-derived tumor EV studies from engineered EV platforms for drug, RNA, cytokine, vaccine, or immune-agonist delivery. Across these areas, we emphasize that robust EV-specific biological interpretations require complementary and methodologically independent characterization, purity and co-isolate assessment, EV-depleted CM, add-back or rescue designs, cargo perturbation, enzymatic controls where appropriate, and dose-normalized functional assays. Advances in microfluidics, immunoaffinity capture, single-vesicle analysis, and multi-omics profiling are improving resolution, but translation will depend on standardized workflows, product- or biomarker-specific validation, scalability, potency metrics, safety, regulatory-grade quality control, and more explicit integration with in vivo and clinically annotated datasets. This article is categorized under: Nanotechnology Approaches to Biology > Nanoscale Systems in Biology Diagnostic Tools > Diagnostic Nanodevices Therapeutic Approaches and Drug Discovery > Nanomedicine for Oncologic Disease.
-
6. Quantum Dots in Ocular Surface: A Systematic Review.
6. 量子点在眼表中的应用：一项系统综述PMID:The current advancements in quantum dot-based ocular surface applications identify critical gaps in existing research. A systematic search was conducted following PRISMA guidelines. Articles were retrieved from PubMed and Scopus using keywords including "quantum dots," "semiconductor nanocrystals," "ocular surface," "tear film," "cornea," "conjunctiva," "lacrimal glands," and "meibomian glands" with Boolean conjunctions. A total of 232 studies were initially selected based on titles and abstracts. After removing duplicates and screening, 21 studies were selected for review. A variety of QDs, including carbon, graphene, silicon, cadmium and gold-based, have been explored for bioimaging and therapeutic applications targeting the ocular surface. Carbon and silicon-based QDs are the most biocompatible. Surface functionalization of these QDs facilitates targeted imaging of tear film layers, conjunctiva, and cornea with stable fluorescence and minimal toxicity. QDs can also be antimicrobial, anti-inflammatory, and scavenge reactive oxygen species which might be used for the treatment of dry eye disease. Although cadmium-based QDs exhibit superior fluorescence, their cytotoxicity limits their clinical application. The optical properties of QDs are influenced by physicochemical properties such as particle size, surface charge, and surface functionalization. QDs represent a promising class of nanoscale materials for diagnostic and therapeutic applications on the ocular surface. While biocompatible variants of QDs, such as carbon and silicon QDs, show potential for clinical use, there is limited information on the standardized synthesis protocols, long-term cytotoxicity, systemic biodistribution, and clearance from ocular tissues. This article is categorized under: Nanotechnology Approaches to Biology > Nanoscale Systems in Biology.
-
7. Principles of Biocompatible Nanotube Design for High-Performance Biomaterials.
7. 高性能生物材料用生物相容性纳米管的设计原理PMID:Nanotubes are one-dimensional tubular structures characterized by nanoscale radial dimensions and micrometer-scale axial lengths. Their hollow inner cavity confers a high specific surface area and distinctive physicochemical properties, enabling remarkable potential in drug delivery, disease diagnostics, and tissue engineering. Extensive research into their biocompatibility and degradability establishes a solid foundation for further development and rational design. A synthesis of current data across relevant systems, including carbon nanotubes (CNTs), boron nitride nanotubes (BNNTs), titanium dioxide nanotubes (TiNTs), halloysite nanotubes (HNTs), anodic aluminium oxide nanotubes (AAOs), lipid nanotubes (LNTs), and polymeric nanotubes (PNTs), reveals how structural features and physicochemical properties govern biological responses and functional performance. This integration supports a unified "structure-property-bioresponse-function" framework, offering a conceptual roadmap and general design principles to guide the next generation of nanotube-based biomaterials.
-
8. Engineering Nanoscale Drug Delivery Systems for Pain.
8. 设计用于疼痛的纳米级药物输送系统PMID:Pain is a pervasive and multifaceted condition that imposes a significant medical and economic burden worldwide. This burden is underscored by the urgent need for transformative, non-addictive opioid alternatives. Nanomedicine offers a promising avenue for addressing the many limitations associated with conventional pain treatments, such as off-target effects, poor bioavailability, and rapid clearance, while enabling advanced therapeutic approaches such as precise spatiotemporal control and robust delivery of biologics. In this review, we explore the convergence of nanomedicine and pain management. We examine current literature on pain and chronic pain physiology and provide collated pharmacological data on current therapeutic approaches as a reference for formulation development. Recent advancements in lipid-based, polymeric, and inorganic nanoscale drug delivery systems (NDDS) for pain are surveyed, along with their progress toward clinical translation. Strategies for enhancing the efficacy of NDDS for pain are discussed, including supramolecular depot localization methods, active and passive targeting, controlled release kinetics, and the incorporation of stimuli-responsive elements for triggered release. We identify knowledge and technical gaps limiting progression beyond sustained-release formulations toward designs exploiting pain-specific biology. Overall, this review provides a comprehensive overview of the state-of-the-art in nanomedicine-based approaches for pain management and provides a roadmap for future innovations.
-
9. Stimuli-Responsive Nanoplatforms for Precision Intervention in Rheumatoid Arthritis.
PMID:Rheumatoid arthritis (RA) is a chronic autoimmune disorder characterized by persistent synovial inflammation and progressive joint destruction. While conventional pharmacotherapies form the cornerstone of RA management, their efficacy is often limited by suboptimal therapeutic outcomes and severe systemic toxicity. In this context, stimuli-responsive nanoplatforms (SR-NPs) have emerged as a promising approach for precision treatment of RA, enabling on-demand drug release triggered by disease-specific endogenous (e.g., pH, ROS, enzymes, GSH, hypoxia) or exogenous (e.g., light, ultrasound, magnetic fields, heat) cues. This review provides a systematic overview of the cutting-edge applications of SR-NPs, categorizing them into endogenous (single- and multi-stimuli), exogenous (single- and multi-stimuli), and hybrid endogenous-exogenous (e.g., ROS/pH/light, GSH/heat) responsive systems. We critically evaluate the design principles, targeting mechanisms, therapeutic payloads, and performance of each category in preclinical RA models. Our analysis reveals that endogenous systems leverage the pathological microenvironment for disease-dependent actuation, exogenous platforms offer tunable spatiotemporal control, while hybrid designs represent an emerging trend toward synergistic and programmable precision. Despite promising advances in enhanced joint retention and effective inflammation suppression, key challenges concerning stimulus heterogeneity, long-term biocompatibility, and clinical translation remain to be addressed. Taken together, this work underscores the evolution of SR-NPs into intelligent and multifaceted therapeutics, thereby providing a potential framework for personalized RA management.
-
10. Nanomedicine for Glioblastoma Therapy: Novel Insights and Future Perspectives.
10. 纳米医学在胶质母细胞瘤治疗中的应用：新见解与未来展望PMID:Glioblastoma (GBM) remains one of the most aggressive primary brain tumors, with poor prognosis, high recurrence, and limited therapeutic options. Although substantial progress has been made in drug development, effective clinical translation is still constrained by inefficient delivery across the blood brain barrier (BBB) and blood brain tumor barrier (BBTB), insufficient tumor accumulation, intratumoral heterogeneity, acquired therapeutic resistance, and dose limiting systemic toxicity. Nanomedicine offers a promising strategy to address these barriers through tunable physicochemical properties, flexible surface functionalization, improved pharmacokinetics, and controllable drug release. In this review, we systematically summarize recent advances in nanomedicine enabled GBM therapy from four interrelated perspectives: the optimization of nanomaterial properties, the development of goal-oriented targeting strategies, the rationalization of delivery routes, and the engineering of smart stimuli-responsive nano-systems. Rather than only cataloguing representative nanoplatforms, we emphasize how material parameters, biological targeting mechanisms, delivery routes, and release behaviors are mechanistically linked to BBB or BBTB penetration, tumor accumulation, therapeutic efficacy, and translational feasibility. Importantly, we also incorporate a key failure case analysis of representative clinical and preclinical studies, highlighting why promising nanotherapeutic concepts may fail because of inadequate intratumoral distribution, insufficient survival benefit, poor patient selection, manufacturing complexity, safety concerns, or impractical trial design. By integrating delivery mechanisms, cross platform comparison, translational barriers, and future optimization principles, this review provides a critical and forward looking framework for the rational design of precise, effective, and clinically translatable nanomedicine strategies for GBM treatment.